These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Grand rounds: Veterans Hospital. Miranda MC Bol Asoc Med P R; 1966 Dec; 58(12):576-81. PubMed ID: 5231580 [No Abstract] [Full Text] [Related]
25. [Cytogenetical and clinico-hematological changes in myeloma disease]. Dubrova SE; Dygin VP; Ushakova EA Tsitologiia; 1966; 8(2):241-9. PubMed ID: 5984072 [No Abstract] [Full Text] [Related]
26. [On the nature of bone regeneration processes in patients with multiple myeloma treated with sarcolysin]. Tager IL; Merkulova NV; Tseshkovskiĭ MS Vestn Rentgenol Radiol; 1965; 40(2):13-7. PubMed ID: 5853760 [No Abstract] [Full Text] [Related]
30. [Therapy results and clinical course in 91 cases of multiple myeloma with regard to their clinical staging (author's transl)]. Rubio Felix D; Giraldo MP; Raichs A; García Zueco JC; Mur P; Faura MV; Ruíz-Marcuello E; Piñan MA Sangre (Barc); 1980; 25(1):25-34. PubMed ID: 7384962 [No Abstract] [Full Text] [Related]
31. Melphalan and its role in the management of patients with multiple myeloma. Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453 [TBL] [Abstract][Full Text] [Related]
32. [Case of IgG-K myeloma successfully treated with melphalan but terminating in acute myelogenous leukemia 2 years and 8 months later]. Saitoh A; Tsushima T; Narita K; Fujiwara S; Kawamura S; Chiba Y; Yoshida Y Rinsho Ketsueki; 1982 Jun; 23(6):862-9. PubMed ID: 6960198 [No Abstract] [Full Text] [Related]
33. Peptichemio in multiple myeloma. (Preliminary results). Cavo M; Gobbi M; Tura S Haematologica; 1981 Apr; 66(2):208-15. PubMed ID: 6791997 [No Abstract] [Full Text] [Related]
34. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation. Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615 [TBL] [Abstract][Full Text] [Related]
35. Melphalan kinetics in hyperthermic isolation perfusion of the extremities. Loos U; Musch E; Rauschecker H; Willenbrock C J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851 [No Abstract] [Full Text] [Related]
36. [Treatment of myelomatosis with melphalan and testosterone. Some biochemical changes in relation to therapeutics]. Rordam P; Thiessen B Folia Clin Int (Barc); 1966; 16(7):339-41. PubMed ID: 5991648 [No Abstract] [Full Text] [Related]
37. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204 [TBL] [Abstract][Full Text] [Related]
38. Auer rod-like intracytoplasmic inclusions in multiple myeloma. A case report and review of the literature. Hütter G; Nowak D; Blau IW; Thiel E Int J Lab Hematol; 2009 Apr; 31(2):236-40. PubMed ID: 18190590 [TBL] [Abstract][Full Text] [Related]
39. Deletion of 5q31 and 7q31 in patients with stable melphalan treated multiple myeloma. Amiel A; Yukla M; Yogev S; Manor Y; Fejgin MD; Lishner M Cancer Genet Cytogenet; 2004 Jul; 152(1):84-7. PubMed ID: 15193449 [TBL] [Abstract][Full Text] [Related]